EUCTR2009-012346-23-FR进行中（未招募）1 期
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, STUDY OF AZACITIDINE(VIDAZA®) VERSUS CONVENTIONAL CARE REGIMENS FOR THE TREATMENT OF OLDERSUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 480
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Diagnosis of one of the following:
- •- Newly diagnosed, histologically confirmed de novo AML or;
- •- AML secondary to prior myelodysplastic disease not treated with azacitidine,
- •decitabine, or cytarabine or;
- •- AML secondary to exposure to potentially leukemogenic therapies or agents (eg,
- •radiation therapy, alkylating agents, topoisomerase II inhibitors) with the primary
- •malignancy in remission for at least 2 years;
- •2. Bone marrow blasts > 30%;
- •3. Male or female subjects = 65 years of age at the time of signing the informed consent document;
- •4. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2;
- •5. Adequate organ function, defined as:
- •- Serum bilirubin = 1.5 times the upper limit of normal (ULN);
- •- Serum aspartate aminotransferase (AST) and alanine aminotransferase (ALT) = 2.5
- •times the ULN;
- •-Serum creatinine = 1.5 times the ULN;
- •6. Females of childbearing potential must:
- •- Agree to the use of a physician-approved contraceptive method (oral, injectable, or
- •implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier
- •contraceptive with spermicide; or vasectomized partner) while on azacitidine; and for
- •3 months following the last dose of azacitidine; and
- •- Have a negative serum pregnancy test within 72 hours prior to starting study therapy.
- •7. Male subjects with a female partner of childbearing potential must agree to the use of a physician-approved contraceptive method throughout the course of the study and avoid fathering a child during the course of the
- •study and for 3 months following the last dose of azacitidine;
- •8. Understand and voluntarily sign an informed consent document prior to any study related assessments/procedures are conducted;
- •9. Able to adhere to the study visit schedule and other protocol requirements.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1. Previous cytotoxic (except hydroxyurea) or biologic treatment for AML;
- •2. Previous treatment with azacitidine, decitabine, or cytarabine;
- •3. Prior use of targeted therapy agents (eg, FLT3 inhibitors, other kinase inhibitors);
- •4. Suspected or proven acute promyelocytic leukemia (FAB M3) based on morphology,
- •immunophenotype, molecular assay, or karyotype;
- •5. AML associated with inv(16), t(8;21), t(16;16), t(15;17), or t(9;22) karyotypes or
- •molecular evidence of such translocations;
- •6. Prior bone marrow or stem cell transplantation;
- •7. White blood cell (WBC) count > 15 x 109/L at screening;
- •8. Proven central nervous system leukemia;
- •9. Inaspirable bone marrow;
- •10. Candidate for allogeneic bone marrow or stem cell transplant;
- •11. Diagnosis of malignant disease within the previous 12 months (excluding basal cell carcinoma of the skin without complications, in-situ” carcinoma of the cervix or breast, or other local malignancy excised or irradiated with a high probability of cure)
- •12. Malignant hepatic tumors;
- •13. Unstable angina, significant cardiac arrhythmia, or New York Heart Association (NYHA) class 3 or 4 congestive heart failure (see Appendix D);
- •14. Pregnant or lactating females;
- •15. Uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing
- •signs/symptoms related to the infection without improvement despite appropriate
- •antibiotics or other treatment);
- •16. Active viral infection with known human immunodeficiency virus (HIV) or viral
- •hepatitis type B or C;
- •17. Known or suspected hypersensitivity to azacitidine or mannitol;
- •18. Use of any other experimental drug or therapy within 28 days prior to Day 1 of Cycle 1;
- •19. Unwilling or unable to complete patient reported outcome assessments without assistance or with minimal assistance from trained site personnel and/or caregiver;
- •20. Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study;
- •21. Any significant medical condition, laboratory abnormality, or psychiatric illness that would interfere or prevent the subject from participating in the study;
- •22. Any condition that confounds the ability to interpret data from the study.
研究者
相似试验
进行中（未招募）
不适用
A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, STUDY OF AZACITIDINE (VIDAZA) VERSUS CONVENTIONAL CARE REGIMENS FOR THE TREATMENT OF OLDER SUBJECTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA - NDEUCTR2009-012346-23-ITCelgene Corporation480
进行中（未招募）
1 期
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)EUCTR2009-012346-23-NLCelgene Corporation480
进行中（未招募）
1 期
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)ewly diagnosed de novo Acute Myeloid Leukemia (AML) or AML secondary to prior myelodysplasticdisease in older subjects with >30% bone marrow blasts and who are not eligible for hematopoietic stem cell transplantation.MedDRA version: 14.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaSystem Organ Class: 100000004864EUCTR2009-012346-23-DECelgene Corporation480
进行中（未招募）
1 期
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)EUCTR2009-012346-23-ATCelgene Corporation480
进行中（未招募）
不适用
Study of Vidaza Versus Conventional Care Regimens for the Treatment of Acute Myeloid Leukemia (AML)EUCTR2009-012346-23-CZCelgene Corporation480